FibroBiologics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
FBLG Nasdaq 2836 www.fibrobiologics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for FibroBiologics, Inc.

FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing - Dec 30th, 2024 9:30 pm
D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing - Dec 30th, 2024 7:12 pm
FibroBiologics Obtains up to $25 Million Financing - Dec 23rd, 2024 3:50 pm
FibroBiologics Announces $25 Million Financing - Dec 23rd, 2024 12:55 pm
FBLG: On Target to Initiate Phase 1/2 Trial in 2025… - Nov 21st, 2024 3:05 pm
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly - Nov 19th, 2024 2:15 pm
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics - Nov 14th, 2024 2:15 pm
Is FibroBiologics (NASDAQ:FBLG) In A Good Position To Deliver On Growth Plans? - Nov 14th, 2024 12:12 pm
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Nov 12th, 2024 9:20 pm
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology - Oct 29th, 2024 1:15 pm
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024 - Oct 28th, 2024 1:31 pm
FibroBiologics and Charles River link for chronic disease therapies manufacture - Oct 21st, 2024 11:45 am
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases - Oct 18th, 2024 12:30 pm
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office - Oct 16th, 2024 1:15 pm
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit - Oct 11th, 2024 1:31 pm
FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa - Sep 30th, 2024 1:31 pm
FibroBiologics Engages Southern Star Research as CRO in Australia - Sep 19th, 2024 1:31 pm
FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology - Sep 12th, 2024 1:31 pm
FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Sep 6th, 2024 1:31 pm
FibroBiologics Announces Filing of Patent Application for Wound Healing Using an Adhesive Bandage with Fibroblast Cell-Based Technology - Aug 20th, 2024 1:31 pm